A customer’s compound had relatively poor solubility as well as poor and variable bioavailability. It is understood that different enhancing technologies can produce varying results, and that testing several is key to identifying the best approach. However, being an emerging pharmaceutical company, the customer could not afford the time and expense of the traditional process of screening technologies one at a time with several vendors.